APA (7th ed.) Citation

Post, F. A., Moyle, G. J., Stellbrink, H. J., Domingo, P., Podzamczer, D., Fisher, M., . . . Lim, M. L. (2010). Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Journal of acquired immune deficiency syndromes (1999), 55(1), 49. https://doi.org/10.1097/QAI.0b013e3181dd911e

Chicago Style (17th ed.) Citation

Post, Frank A., et al. "Randomized Comparison of Renal Effects, Efficacy, and Safety with Once-daily Abacavir/lamivudine Versus Tenofovir/emtricitabine, Administered with Efavirenz, in Antiretroviral-naive, HIV-1-infected Adults: 48-week Results from the ASSERT Study." Journal of Acquired Immune Deficiency Syndromes (1999) 55, no. 1 (2010): 49. https://doi.org/10.1097/QAI.0b013e3181dd911e.

MLA (9th ed.) Citation

Post, Frank A., et al. "Randomized Comparison of Renal Effects, Efficacy, and Safety with Once-daily Abacavir/lamivudine Versus Tenofovir/emtricitabine, Administered with Efavirenz, in Antiretroviral-naive, HIV-1-infected Adults: 48-week Results from the ASSERT Study." Journal of Acquired Immune Deficiency Syndromes (1999), vol. 55, no. 1, 2010, p. 49, https://doi.org/10.1097/QAI.0b013e3181dd911e.